Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1044 of 6351
-
New drug aims to ease symptoms of rare mast cell disease
Symptom relief OngoingThis is a Phase 2, randomized, double-blind, placebo-controlled study comparing the efficacy and safety of avapritinib + best supportive care (BSC) with placebo + BSC in patients with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by BSC. The st…
Phase 2 • Sponsor: Blueprint Medicines Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Can a drug combo stop prostate cancer from coming back?
Disease control OngoingPatients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive disease features will receive salvage radiation therapy and standard androgen deprivation therapy (ADT) or enhanced ADT to determine if there is any improvement in progression-free surviv…
Phase 2 • Sponsor: RTOG Foundation, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
40,000-Person study aims to stop two cancers before they start
Prevention By invitation onlyGastric cancer is a global health threat. Helicobacter pylori is now recognized as the main risk factor that initiates this process; hence, H. pylori eradication has been considered the most effective method to ameliorate the burden of gastric cancer. Serum pepsinogen levels reve…
Sponsor: National Taiwan University Hospital • Aim: Prevention
Last updated Jun 27, 2026 08:05 UTC
-
Chemo cocktail aimed at zapping pancreatic cysts
Disease control Stopped earlyThe purpose of this study is to evaluate the efficacy and safety of chemotherapeutic pancreatic cyst ablation using ethanol lavage followed by the infusion of a dual-agent chemotherapeutic cocktail (paclitaxel + gemcitabine) compared with alcohol-free saline lavage followed by in…
Phase 3 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New pill may keep soft tissue sarcoma in check after chemo
Disease control CompletedAnlotinib is a multi-target receptor tyrosine kinase inhibitor. It can inhibit the angiogenesis related kinase, such as Vascular Endothelial Growth Factor Receptor (VEGFR), Fibroblast Growth Factor Receptor(FGFR), Platelet-Derived Growth Factor Receptor(PDGFR), and tumor cell pro…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Immunotherapy boosts standard treatment for rectal cancer?
Disease control OngoingThis is a phase II, prospective, open label, one-center study for evaluation of the addition of nivolumab to the chemotherapy phase of the neoadjuvant treatment for locally advanced rectal cancer patients. Subjects must have received no prior treatment for rectal cancer (chemothe…
Phase 2 • Sponsor: Baruch Brenner • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Virus and immunotherapy combo shows promise for Hard-to-Treat cancers
Disease control OngoingThe safety run-in portion of this study is designed to identify the optimal dose of VSV-IFNβ-NIS in combination with pembrolizumab in patients with solid tumors and follows the 3+3 design. The expansion portion will use one-sample binomial designs to assess the efficacy of the co…
Phase 1/2 • Sponsor: Vyriad, Inc. • Aim: Disease control
Last updated Jun 26, 2026 18:34 UTC
-
Sleep apnea clues may unmask hidden heart risks in survivors
Knowledge-focused CompletedThe AMISLEEP study is nested in the "FRENCHIE" registry. The objective is to use routine clinical and polygraphic data to capture SDB/SAS (Sleep Disordered Breathing/Sleep Apnea Syndrome) physiological heterogeneity in relation to clinically relevant cardiovascular outcomes. Sp…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC
-
Engineered donor cells aim to make stem cell transplants safer for blood cancer patients
Disease control Recruiting nowThis study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.
Phase 1 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can a short video and counseling session reduce HIV stigma in pregnancy care?
Disease control CompletedThis study will pilot test a brief, scalable intervention called Maisha (Swahili for life), to address HIV stigma for women presenting to antenatal care in Tanzania and male partners who accompany them. The intervention will include: 1) a video and brief counseling that addresses…
Sponsor: University of Utah • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Time-Restricted eating: a simple diet hack to reverse prediabetes?
Disease control CompletedIn a randomized controlled trial, the investigators intend to measure the health impact of TRE in patients with metabolic syndrome (with three or more of the following criteria: increased waist circumference, abnormal cholesterol levels, elevated blood pressure, or elevated blood…
Sponsor: University of California, San Diego • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New hope for kids with arthritis: baricitinib Long-Term trial underway
Disease control Recruiting nowThe reason for this study is to see if the study drug baricitinib is safe and effective in the treatment of JIA in participants ages 1 to 17. This study is for participants that have been enrolled in studies I4V-MC-JAHV (NCT03773978) or I4V-MC-JAHU.
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Lung cancer trial asks: is it better to start with immunotherapy alone?
Disease control OngoingThis phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Experimental 'In-Situ' vaccine aims to train immune system against three cancers
Disease control CompletedThis is a combination of 4 therapies, three of which are used to treat a single "target site" of your cancer (such as a lymph node or a single tumor), and the 4th is given directly into the blood stream (intravenous or "IV"). 1. Radiation: The target site --lymph node or tumor (…
Phase 1/2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug combo shows promise for resistant ovarian cancer
Disease control CompletedThis is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination w…
Phase 2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Can Parents' everyday talk rewire young brains to boost language?
Disease control CompletedThe objective of the proposed study is to evaluate the efficacy of the Enhanced Milieu Teaching-Sentence Focus (EMT-SF) intervention, implemented by caregivers and interventionists, relative to a control condition enrolling 108 30-month-old children and their caregivers. The cent…
Phase 2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New drug shows promise for controlling psoriatic arthritis symptoms
Disease control CompletedThis is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of subjects with active Psoriatic Arthritis (PsA).
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug cocktail aims to delay chemo in metastatic breast cancer
Disease control OngoingThe goal of this protocol is to evaluate the safety and efficacy of an alternative systemic combination approach that omits or delays the use of chemotherapy in metastatic disease, while improving efficacy and durability of response. The approach combines two potentially effectiv…
Phase 2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New hope for tough leukemia: drug combo shows promise in early trial
Disease control Stopped earlyThis phase I/II trial studies the side effects and best dose of venetoclax and how well it works in combination with low-intensity chemotherapy in patients with B- or T-cell acute lymphoblastic leukemia that has not responded to treatment or that has come back. Venetoclax may sto…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Gene therapy trial for rare childhood disease halted Mid-Study
Disease control PausedRGX-111 is a gene therapy which is intended to deliver a functional copy of the α-L-iduronidase (IDUA) gene to the central nervous system. This is a safety and dose ranging study to determine whether RGX-111 is safe and tolerated by patients with MPS I.
Phase 1/2 • Sponsor: REGENXBIO Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC